Phase 3 CagriSema Trial With Cagrilintide Now Active, Not Recruiting

A Phase 3 clinical trial involving cagrilintide, part of the CagriSema combination, was listed with updated status as of September 30, 2026. The study, registered as NCT07011667, is titled "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term." According to the registry, the trial is currently classified as active but not recruiting. The study is designated as a Phase 3 trial. No results have been posted in connection with this update. Cagrilintide remains an unapproved compound used only in research settings at this stage. This update reflects only the trial's recruitment status change, not any outcome data or conclusions about weight loss effects. Readers should note that status changes in clinical trial registries indicate administrative or enrollment phase transitions, not efficacy findings. Further updates to this trial may be released as the study progresses through its stages. For more background on cagrilintide, its research status, and how it fits into ongoing obesity research, readers can refer to the compound overview.